FDA has approved non-prescription esomeprazole 20mg (Nexium 24HR, Pfizer).
FDA has approved over-the-counter (OTC) esomeprazole 20mg (Nexium 24HR, Pfizer).
Pfizer acquired exclusive global rights from AstraZeneca in 2012 to market non-prescription Nexium, a popular medication for people suffering frequent heartburn.
“Switching medicines, whenever appropriate, from prescription to non-prescription status improves access, empowers consumers to care for their own health, and is an important strategy for Pfizer,” said Paul Sturman, president, Pfizer Consumer Healthcare. “The FDA approval of Nexium 24HR is a significant milestone in executing against our plan.”
In 2013 global sales of Nexium reached $7.8 billion and was ranked number 6th in sales volume worldwide, according to IMS Health MIDAS (December 2013).
Sturman said the non-prescription Nexium will be available in the United States this year.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More